adalimumab-aaty (Yuflyma) vs adalimumab-afzb (Abrilada)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Rheumatoid Arthritis

Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline

adalimumab-aaty (Yuflyma)

Marketed by Celltrion

Approved in Rheumatoid Arthritismonoclonal antibody
Partial signal

NCT03789292 · Phase 3 · completed

This randomized, double-blind Phase 3 equivalence trial compared CT-P17 (Yuflyma) with EU-approved Humira in 648 adults with active rheumatoid arthritis. The primary endpoint was ACR20 response at week 24, and equivalence required the confidence interval of the difference to fall inside predefined margins. ACR20 response was 82.7% in both groups; the 95% CI (-5.94 to 5.94) and the 90% CI (-4.98 to 4.98) were inside the margins, so equivalence was shown and the primary endpoint was met. Source: the peer-reviewed trial report (Kay 2021).

Reported efficacy

American College of Rheumatology(ACR)20 Response Rate at Week 24.: ACR20 response at week 24, CT-P17 vs EU-adalimumab (ITT): 82.7% (268/324) in both groups; treatment difference 95% CI -5.94 to 5.94 (margin -15 to 15%) and 90% CI -4.98 to 4.98 (margin -12 to 15%), both within the predefined equivalence margins (Kay 2021, Arthritis Res Ther). (met)

Result source: NCT03789292

adalimumab-afzb (Abrilada)

Marketed by Pfizer

Approved in Rheumatoid Arthritismonoclonal antibody
Reliable signal

NCT02480153 · Phase 3 · completed

This was a randomized, quadruple-blind, active-controlled Phase 3 trial in 597 patients comparing PF-06410293 with adalimumab-EU on a hard clinical endpoint: ACR20 response at Week 12. The primary equivalence analysis succeeded, with the 95% confidence interval for the response rate difference falling entirely within the prespecified -14% to +14% margin (observed difference -2.98%, 95% CI -10.38% to 4.44%). The large sample size, blinding, active comparator, and met primary endpoint together provide strong evidence of equivalent efficacy.

Reported efficacy

Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12: Period 1: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12: Period 1 (Week 12): Period 1: PF-06410293 68.35% vs Period 1: Adalimumab-EU 71.33% (met)

Result source: NCT02480153

Results for Rheumatoid Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumab-aaty (Yuflyma)adalimumab-afzb (Abrilada)
ACR2082.7% vs 82.7%vs Humirawk 24 · n 324NCT0378929268.3% vs 71.3%vs Adalimumab-EUwk 12 · n 297NCT02480153
11 other results
  • 82.7% vs 79.3% wk 52 · n 283 · Phase 3 · secondary NCT02480153
  • 82.3% vs 78.5% wk 44 · n 283 · Phase 3 · secondary NCT02480153
  • 83.4% vs 77.8% wk 36 · n 283 · Phase 3 · secondary NCT02480153
  • 86.6% vs 82.2% wk 30 · n 283 · Phase 3 · secondary NCT02480153
  • 83.5% vs 78% wk 26 · n 297 · Phase 3 · secondary NCT02480153
  • 86.6% vs 84.4% wk 26 · n 283 · Phase 3 · secondary NCT02480153
  • 78.1% vs 73.7% wk 18 · n 297 · Phase 3 · secondary NCT02480153
  • 69.4% vs 68% wk 8 · n 297 · Phase 3 · secondary NCT02480153
  • 61.3% vs 59.7% wk 6 · n 297 · Phase 3 · secondary NCT02480153
  • 51.9% vs 52.3% wk 4 · n 297 · Phase 3 · secondary NCT02480153
  • 31.3% vs 32% wk 2 · n 297 · Phase 3 · secondary NCT02480153
ACR50—Not reported62.9% vs 55.6%vs Adalimumab-EUwk 52 · n 283NCT02480153
11 other results
  • 64.3% vs 49.6% wk 44 · n 283 · Phase 3 · secondary NCT02480153
  • 61.1% vs 51.9% wk 36 · n 283 · Phase 3 · secondary NCT02480153
  • 59.7% vs 49.6% wk 30 · n 283 · Phase 3 · secondary NCT02480153
  • 59.6% vs 54.7% wk 26 · n 297 · Phase 3 · secondary NCT02480153
  • 61.8% vs 56.3% wk 26 · n 283 · Phase 3 · secondary NCT02480153
  • 45.1% vs 47% wk 18 · n 297 · Phase 3 · secondary NCT02480153
  • 39.7% vs 39.7% wk 12 · n 297 · Phase 3 · secondary NCT02480153
  • 34% vs 33.3% wk 8 · n 297 · Phase 3 · secondary NCT02480153
  • 27.6% vs 27.3% wk 6 · n 297 · Phase 3 · secondary NCT02480153
  • 17.8% vs 14.3% wk 4 · n 297 · Phase 3 · secondary NCT02480153
  • 8.4% vs 6% wk 2 · n 297 · Phase 3 · secondary NCT02480153
ACR70—Not reported36.4% vs 31.9%vs Adalimumab-EUwk 52 · n 283NCT02480153
11 other results
  • 38.5% vs 32.6% wk 44 · n 283 · Phase 3 · secondary NCT02480153
  • 36% vs 26.7% wk 36 · n 283 · Phase 3 · secondary NCT02480153
  • 33.9% vs 30.4% wk 30 · n 283 · Phase 3 · secondary NCT02480153
  • 29.6% vs 31% wk 26 · n 297 · Phase 3 · secondary NCT02480153
  • 31.1% vs 30.4% wk 26 · n 283 · Phase 3 · secondary NCT02480153
  • 21.5% vs 22% wk 18 · n 297 · Phase 3 · secondary NCT02480153
  • 16.5% vs 19% wk 12 · n 297 · Phase 3 · secondary NCT02480153
  • 12.5% vs 11.7% wk 8 · n 297 · Phase 3 · secondary NCT02480153
  • 8.1% vs 8.7% wk 6 · n 297 · Phase 3 · secondary NCT02480153
  • 3.7% vs 3.7% wk 4 · n 297 · Phase 3 · secondary NCT02480153
  • 0.7% vs 2% wk 2 · n 297 · Phase 3 · secondary NCT02480153
DAS28-CRP remission—Not reported—Not reported
HAQ-DI, change—Not reported-0.7 vs -0.7vs Adalimumab-EUwk 52 · n 283NCT02480153
11 other results
  • -0.7 vs -0.7 wk 44 · n 283 · Phase 3 · secondary NCT02480153
  • -0.7 vs -0.7 wk 36 · n 283 · Phase 3 · secondary NCT02480153
  • -0.7 vs -0.7 wk 30 · n 283 · Phase 3 · secondary NCT02480153
  • -0.7 vs -0.7 wk 26 · n 297 · Phase 3 · secondary NCT02480153
  • -0.7 vs -0.7 wk 26 · n 283 · Phase 3 · secondary NCT02480153
  • -0.6 vs -0.6 wk 18 · n 297 · Phase 3 · secondary NCT02480153
  • -0.5 vs -0.5 wk 12 · n 297 · Phase 3 · secondary NCT02480153
  • -0.5 vs -0.5 wk 8 · n 297 · Phase 3 · secondary NCT02480153
  • -0.4 vs -0.5 wk 6 · n 297 · Phase 3 · secondary NCT02480153
  • -0.3 vs -0.4 wk 4 · n 297 · Phase 3 · secondary NCT02480153
  • -0.3 vs -0.3 wk 2 · n 297 · Phase 3 · secondary NCT02480153
Modified Sharp score, change—Not reported—Not reported

ACR20

adalimumab-aaty (Yuflyma)
82.7% vs 82.7%vs Humirawk 24 · n 324NCT03789292
adalimumab-afzb (Abrilada)
68.3% vs 71.3%vs Adalimumab-EUwk 12 · n 297NCT02480153
11 other results
  • 82.7% vs 79.3% wk 52 · n 283 · Phase 3 · secondary NCT02480153
  • 82.3% vs 78.5% wk 44 · n 283 · Phase 3 · secondary NCT02480153
  • 83.4% vs 77.8% wk 36 · n 283 · Phase 3 · secondary NCT02480153
  • 86.6% vs 82.2% wk 30 · n 283 · Phase 3 · secondary NCT02480153
  • 83.5% vs 78% wk 26 · n 297 · Phase 3 · secondary NCT02480153
  • 86.6% vs 84.4% wk 26 · n 283 · Phase 3 · secondary NCT02480153
  • 78.1% vs 73.7% wk 18 · n 297 · Phase 3 · secondary NCT02480153
  • 69.4% vs 68% wk 8 · n 297 · Phase 3 · secondary NCT02480153
  • 61.3% vs 59.7% wk 6 · n 297 · Phase 3 · secondary NCT02480153
  • 51.9% vs 52.3% wk 4 · n 297 · Phase 3 · secondary NCT02480153
  • 31.3% vs 32% wk 2 · n 297 · Phase 3 · secondary NCT02480153

ACR50

adalimumab-aaty (Yuflyma)
—Not reported
adalimumab-afzb (Abrilada)
62.9% vs 55.6%vs Adalimumab-EUwk 52 · n 283NCT02480153
11 other results
  • 64.3% vs 49.6% wk 44 · n 283 · Phase 3 · secondary NCT02480153
  • 61.1% vs 51.9% wk 36 · n 283 · Phase 3 · secondary NCT02480153
  • 59.7% vs 49.6% wk 30 · n 283 · Phase 3 · secondary NCT02480153
  • 59.6% vs 54.7% wk 26 · n 297 · Phase 3 · secondary NCT02480153
  • 61.8% vs 56.3% wk 26 · n 283 · Phase 3 · secondary NCT02480153
  • 45.1% vs 47% wk 18 · n 297 · Phase 3 · secondary NCT02480153
  • 39.7% vs 39.7% wk 12 · n 297 · Phase 3 · secondary NCT02480153
  • 34% vs 33.3% wk 8 · n 297 · Phase 3 · secondary NCT02480153
  • 27.6% vs 27.3% wk 6 · n 297 · Phase 3 · secondary NCT02480153
  • 17.8% vs 14.3% wk 4 · n 297 · Phase 3 · secondary NCT02480153
  • 8.4% vs 6% wk 2 · n 297 · Phase 3 · secondary NCT02480153

ACR70

adalimumab-aaty (Yuflyma)
—Not reported
adalimumab-afzb (Abrilada)
36.4% vs 31.9%vs Adalimumab-EUwk 52 · n 283NCT02480153
11 other results
  • 38.5% vs 32.6% wk 44 · n 283 · Phase 3 · secondary NCT02480153
  • 36% vs 26.7% wk 36 · n 283 · Phase 3 · secondary NCT02480153
  • 33.9% vs 30.4% wk 30 · n 283 · Phase 3 · secondary NCT02480153
  • 29.6% vs 31% wk 26 · n 297 · Phase 3 · secondary NCT02480153
  • 31.1% vs 30.4% wk 26 · n 283 · Phase 3 · secondary NCT02480153
  • 21.5% vs 22% wk 18 · n 297 · Phase 3 · secondary NCT02480153
  • 16.5% vs 19% wk 12 · n 297 · Phase 3 · secondary NCT02480153
  • 12.5% vs 11.7% wk 8 · n 297 · Phase 3 · secondary NCT02480153
  • 8.1% vs 8.7% wk 6 · n 297 · Phase 3 · secondary NCT02480153
  • 3.7% vs 3.7% wk 4 · n 297 · Phase 3 · secondary NCT02480153
  • 0.7% vs 2% wk 2 · n 297 · Phase 3 · secondary NCT02480153

DAS28-CRP remission

adalimumab-aaty (Yuflyma)
—Not reported
adalimumab-afzb (Abrilada)
—Not reported

HAQ-DI, change

adalimumab-aaty (Yuflyma)
—Not reported
adalimumab-afzb (Abrilada)
-0.7 vs -0.7vs Adalimumab-EUwk 52 · n 283NCT02480153
11 other results
  • -0.7 vs -0.7 wk 44 · n 283 · Phase 3 · secondary NCT02480153
  • -0.7 vs -0.7 wk 36 · n 283 · Phase 3 · secondary NCT02480153
  • -0.7 vs -0.7 wk 30 · n 283 · Phase 3 · secondary NCT02480153
  • -0.7 vs -0.7 wk 26 · n 297 · Phase 3 · secondary NCT02480153
  • -0.7 vs -0.7 wk 26 · n 283 · Phase 3 · secondary NCT02480153
  • -0.6 vs -0.6 wk 18 · n 297 · Phase 3 · secondary NCT02480153
  • -0.5 vs -0.5 wk 12 · n 297 · Phase 3 · secondary NCT02480153
  • -0.5 vs -0.5 wk 8 · n 297 · Phase 3 · secondary NCT02480153
  • -0.4 vs -0.5 wk 6 · n 297 · Phase 3 · secondary NCT02480153
  • -0.3 vs -0.4 wk 4 · n 297 · Phase 3 · secondary NCT02480153
  • -0.3 vs -0.3 wk 2 · n 297 · Phase 3 · secondary NCT02480153

Modified Sharp score, change

adalimumab-aaty (Yuflyma)
—Not reported
adalimumab-afzb (Abrilada)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. adalimumab-aaty (Yuflyma): 5 of 5 rows · adalimumab-afzb (Abrilada): 3 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricadalimumab-aaty (Yuflyma)adalimumab-afzb (Abrilada)
DAS28-CRP
absolute change · score
-2.945 vs -3.074 Humira score @ 52wka,b,c
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
show 1 more dose
-2.983 vs -3.074 Humira score @ 52wk
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
-2.9 vs -2.9 Adalimumab-EU score @ 52wkb,c
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
Dropout rate
6.5%CT-P17 Subcutaneous(SC) (Adalimuma
NCT03789292 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 4 more results
—Switched to CT-P17
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
—Treatment 1: CT-P17
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
—Treatment 2: CT-P17 Maintenance
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
—Treatment 2: Switched to CT-P17
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
—Period 1: PF-06410293d
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 3 more results
—Period 2: PF-06410293/PF-06410293
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—Period 3: PF-06410293/PF-06410293/
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—
NCT04230213 · Phase 3
Discontinued due to AEs
2.2%CT-P17 Subcutaneous(SC) (Adalimuma
NCT03789292 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 4 more results
—Switched to CT-P17
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
—Treatment 1: CT-P17
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
—Treatment 2: CT-P17 Maintenance
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
—Treatment 2: Switched to CT-P17
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
—Period 1: PF-06410293d
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 3 more results
—Period 2: PF-06410293/PF-06410293
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—Period 3: PF-06410293/PF-06410293/
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—
NCT04230213 · Phase 3
Serious AEs
—CT-P17 Subcutaneous(SC) (Adalimuma
NCT03789292 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 4 more results
—Switched to CT-P17
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
3.7%Treatment 1: CT-P17
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
2%Treatment 2: CT-P17 Maintenance
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
3.3%Treatment 2: Switched to CT-P17
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
4%Period 1: PF-06410293d
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 3 more results
1.4%Period 2: PF-06410293/PF-06410293
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
3.5%Period 3: PF-06410293/PF-06410293/
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
1.4%
NCT04230213 · Phase 3
Most frequent reported AEs
upper respiratory tract infection 5.6%
nasopharyngitis 5.2%
injection site reaction 4.9%
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
show 2 more results
neutropenia 5%
upper respiratory tract infection 3.3%
urinary tract infection 3%
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
neutropenia 5.3%
alanine aminotransferase increased 4.6%
leukopenia 4.6%
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
d
viral upper respiratory tract infection 7.1%
rheumatoid arthritis 1.7%
nasopharyngitis 0%
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 3 more results
viral upper respiratory tract infection 5.3%
rheumatoid arthritis 1.4%
nasopharyngitis 0.4%
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
nasopharyngitis 5%
rheumatoid arthritis 4.7%
viral upper respiratory tract infection 0.4%
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
sars-cov-2 test positive 8.5%
covid-19 7.5%
erythema 2.8%
NCT04230213 · Phase 3

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation context differs: baseline_threshold differs (hscrp_mg_l>=8, swollen_joint_count>=6, tender_joint_count>=6 versus none recorded); prior_therapy differs (experienced versus naive).
  3. cTreatment context has not been resolved for both arms.
  4. dPopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

adalimumab-afzb (Abrilada)

ACR20 88.4% (n=259) @ 52wk
responder rate · % of participants
No placebo or comparator arm
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 229 Participants as posted
show 4 more results
88.8% (n=259) @ 56wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 230 Participants as posted
87.3% (n=259) @ 66wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 226 Participants as posted
84.6% (n=259) @ 76wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 219 Participants as posted
83.4% (n=259) @ 78wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 216 Participants as posted
ACR50 8.4% (n=297) vs 6% (n=300) Adalimumab-EU @ 2wk
responder rate · % of participants
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 25 Participants as posted
show 11 more results
17.8% (n=297) vs 14.3% (n=300) Adalimumab-EU @ 4wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 53 Participants as posted
27.6% (n=297) vs 27.3% (n=300) Adalimumab-EU @ 6wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 82 Participants as posted
34% (n=297) vs 33.3% (n=300) Adalimumab-EU @ 8wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 101 Participants as posted
39.7% (n=297) vs 39.7% (n=300) Adalimumab-EU @ 12wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 118 Participants as posted
45.1% (n=297) vs 47% (n=300) Adalimumab-EU @ 18wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 134 Participants as posted
59.6% (n=297) vs 54.7% (n=300) Adalimumab-EU @ 26wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 177 Participants as posted
61.8% (n=283) vs 56.3% (n=135) Adalimumab-EU @ 26wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 175 Participants as posted
59.7% (n=283) vs 49.6% (n=135) Adalimumab-EU @ 30wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 169 Participants as posted
61.1% (n=283) vs 51.9% (n=135) Adalimumab-EU @ 36wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 173 Participants as posted
64.3% (n=283) vs 49.6% (n=135) Adalimumab-EU @ 44wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 182 Participants as posted
62.9% (n=283) vs 55.6% (n=135) Adalimumab-EU @ 52wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 178 Participants as posted
ACR50 68.3% (n=259) @ 52wk
responder rate · % of participants
No placebo or comparator arm
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 177 Participants as posted
show 4 more results
67.6% (n=259) @ 56wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 175 Participants as posted
68.3% (n=259) @ 66wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 177 Participants as posted
69.1% (n=259) @ 76wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 179 Participants as posted
71.4% (n=259) @ 78wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 185 Participants as posted
ACR70 0.7% (n=297) vs 2% (n=300) Adalimumab-EU @ 2wk
responder rate · % of participants
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 2 Participants as posted
show 11 more results
3.7% (n=297) vs 3.7% (n=300) Adalimumab-EU @ 4wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 11 Participants as posted
8.1% (n=297) vs 8.7% (n=300) Adalimumab-EU @ 6wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 24 Participants as posted
12.5% (n=297) vs 11.7% (n=300) Adalimumab-EU @ 8wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 37 Participants as posted
16.5% (n=297) vs 19% (n=300) Adalimumab-EU @ 12wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 49 Participants as posted
21.5% (n=297) vs 22% (n=300) Adalimumab-EU @ 18wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 64 Participants as posted
29.6% (n=297) vs 31% (n=300) Adalimumab-EU @ 26wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 88 Participants as posted
31.1% (n=283) vs 30.4% (n=135) Adalimumab-EU @ 26wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 88 Participants as posted
33.9% (n=283) vs 30.4% (n=135) Adalimumab-EU @ 30wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 96 Participants as posted
36% (n=283) vs 26.7% (n=135) Adalimumab-EU @ 36wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 102 Participants as posted
38.5% (n=283) vs 32.6% (n=135) Adalimumab-EU @ 44wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 109 Participants as posted
36.4% (n=283) vs 31.9% (n=135) Adalimumab-EU @ 52wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 103 Participants as posted
ACR70 39.8% (n=259) @ 52wk
responder rate · % of participants
No placebo or comparator arm
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 103 Participants as posted
show 4 more results
39% (n=259) @ 56wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 101 Participants as posted
43.2% (n=259) @ 66wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 112 Participants as posted
45.6% (n=259) @ 76wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 118 Participants as posted
49.4% (n=259) @ 78wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 128 Participants as posted
Tender Joint Count -7.5 vs -7.1 Adalimumab-EU joints @ 2wk
absolute change · joints
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 11 more results
-10.2 vs -10.7 Adalimumab-EU joints @ 4wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-12.8 vs -13.1 Adalimumab-EU joints @ 6wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-14.2 vs -15.2 Adalimumab-EU joints @ 8wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-15.4 vs -16.1 Adalimumab-EU joints @ 12wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-16.8 vs -17.3 Adalimumab-EU joints @ 18wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-18.4 vs -19.2 Adalimumab-EU joints @ 26wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-18.4 vs -20.1 Adalimumab-EU joints @ 26wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-19 vs -19.5 Adalimumab-EU joints @ 30wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-18.7 vs -20.1 Adalimumab-EU joints @ 36wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-19.4 vs -21.5 Adalimumab-EU joints @ 44wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-18.9 vs -21 Adalimumab-EU joints @ 52wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
Tender Joint Count -19.3 joints @ 52wk
absolute change · joints
No placebo or comparator arm
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 4 more results
-19.4 joints @ 56wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-19.5 joints @ 66wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-20.6 joints @ 76wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-20.5 joints @ 78wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
Swollen Joint Count -5.7 vs -6.1 Adalimumab-EU joints @ 2wk
absolute change · joints
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 11 more results
-7.7 vs -8.2 Adalimumab-EU joints @ 4wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-9 vs -9.7 Adalimumab-EU joints @ 6wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-9.8 vs -11 Adalimumab-EU joints @ 8wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-10.4 vs -11.8 Adalimumab-EU joints @ 12wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-11.3 vs -13 Adalimumab-EU joints @ 18wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-12.2 vs -13.6 Adalimumab-EU joints @ 26wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-12.2 vs -13.6 Adalimumab-EU joints @ 26wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-12.3 vs -13.3 Adalimumab-EU joints @ 30wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-12.4 vs -14.2 Adalimumab-EU joints @ 36wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-12.8 vs -14.7 Adalimumab-EU joints @ 44wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-12.6 vs -14.2 Adalimumab-EU joints @ 52wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
Swollen Joint Count -12.8 joints @ 52wk
absolute change · joints
No placebo or comparator arm
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 4 more results
-12.9 joints @ 56wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-13 joints @ 66wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-13.3 joints @ 76wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-13.4 joints @ 78wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
Physician Global Assessment -20.7 vs -20.5 Adalimumab-EU score @ 2wk
absolute change · score
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 11 more results
-28.9 vs -29 Adalimumab-EU score @ 4wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-32.6 vs -33 Adalimumab-EU score @ 6wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-35.6 vs -37.1 Adalimumab-EU score @ 8wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-40.4 vs -40.5 Adalimumab-EU score @ 12wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-44.2 vs -44.2 Adalimumab-EU score @ 18wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-47.2 vs -46.5 Adalimumab-EU score @ 26wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-47.7 vs -45.5 Adalimumab-EU score @ 26wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-47.9 vs -46.5 Adalimumab-EU score @ 30wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-47.3 vs -45.4 Adalimumab-EU score @ 36wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-49.1 vs -46.9 Adalimumab-EU score @ 44wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-47.9 vs -48.4 Adalimumab-EU score @ 52wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
Physician Global Assessment -48.9 score @ 52wk
absolute change · score
No placebo or comparator arm
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 4 more results
-50.5 score @ 56wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-49.4 score @ 66wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-50.9 score @ 76wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-52.3 score @ 78wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
Patient Assessment of Arthritis Pain -13.1 vs -13.9 Adalimumab-EU score @ 2wk
absolute change · score
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 11 more results
-18.5 vs -17.4 Adalimumab-EU score @ 4wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-21.9 vs -21.7 Adalimumab-EU score @ 6wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-24.8 vs -25.5 Adalimumab-EU score @ 8wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-28.8 vs -28.5 Adalimumab-EU score @ 12wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-31.5 vs -31.4 Adalimumab-EU score @ 18wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-35.1 vs -33.5 Adalimumab-EU score @ 26wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-35.4 vs -32.4 Adalimumab-EU score @ 26wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-36.3 vs -34.1 Adalimumab-EU score @ 30wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-35.5 vs -34.9 Adalimumab-EU score @ 36wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-38.6 vs -35.7 Adalimumab-EU score @ 44wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-37.4 vs -36.8 Adalimumab-EU score @ 52wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3

+ 44 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab-aaty (Yuflyma)'s landscape · adalimumab-afzb (Abrilada)'s landscape